First four failures of cefathiamidine to treat urogenital gonorrhoea in Guangzhou, China, 2014–15
Jingyao Liang A B C , Ridong Yang A B C , Xiaodong Li A B , Chao Bi A B , Xingdong Ye A B , Xibao Zhang A B D and Wenling Cao A B D
+ Author Affiliations
- Author Affiliations
A Institute of Dermatology, Guangzhou Medical University, Guangzhou 510095, 56 Hengfu Road, Guangzhou 510095, China.
B Department of Dermatology, Guangzhou Institute of Dermatology, 56 Hengfu Road, Guangzhou 510095, China.
C These two authors contributed equally to this work.
D Corresponding authors. Email: gzpfbfzs@yahoo.com; Cllaz@163.com
Sexual Health 14(3) 289-292 https://doi.org/10.1071/SH16087
Submitted: 18 May 2016 Accepted: 18 January 2017 Published: 7 April 2017
Abstract
Neisseria gonorrhoeae has a remarkable ability to develop resistance to all available therapeutic antimicrobials. This report describes the first four cases of verified failure to treat gonorrhoea using 1000 mg cefathiamidine intramuscularly in Guangzhou, China; for each case, the patient was clinically cured after treatment with 500 mg ceftriaxone intramuscularly. Enhanced monitoring of clinical treatment failures, finding new effective treatments and updating treatment guidelines are all of utmost importance to curb the spread of drug-resistant gonorrhoea.
Additional keywords: antimicrobial resistance, Neisseria gonorrhoeae, treatment failure.
References
[1] Golparian D, Ohlsson A, Janson H, Lidbrink P, Richtner T, Ekelund O, Fredlund H, Unemo M. Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014. Euro Surveill 2014; 19 20874[2] Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011; 16 19833
[3] Chen MY, Stevens K, Tideman R, Zaia A, Tomita T, Fairley CK, Lahra M, Whiley D, Hogg G. Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother 2013; 68 1445–7.
| Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXnvVyqtbg%3D&md5=2101ac4dc49395e182d885f07aa1f733CAS |
[4] van Dam AP, van Ogtrop ML, Golparian D, Mehrtens J, de Vries HJ, Unemo M. Verified clinical failure with cefotaxime 1g for treatment of gonorrhoea in the Netherlands: a case report. Sex Transm Infect 2014; 90 513–4.
| Verified clinical failure with cefotaxime 1g for treatment of gonorrhoea in the Netherlands: a case report.Crossref | GoogleScholarGoogle Scholar |
[5] Chen SC, Yin YP, Dai XQ, Unemo M, Chen XS. First nationwide study regarding ceftriaxone resistance and molecular epidemiology of Neisseria gonorrhoeae in China. J Antimicrob Chemother 2016; 71 92–9.
| First nationwide study regarding ceftriaxone resistance and molecular epidemiology of Neisseria gonorrhoeae in China.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC28Xjs1Ohtb8%3D&md5=b93efa5dbc1219f69ee2c15305e64e90CAS |
[6] Liang JY, Cao WL, Li XD, Bi C, Yang RD, Liang YH, Li P, Ye XD, Chen XX, Zhang XB. Azithromycin-resistant Neisseria gonorrhoeae isolates in Guangzhou, China (2009–2013): coevolution with decreased susceptibilities to ceftriaxone and genetic characteristics. BMC Infect Dis 2016; 16 152
| Azithromycin-resistant Neisseria gonorrhoeae isolates in Guangzhou, China (2009–2013): coevolution with decreased susceptibilities to ceftriaxone and genetic characteristics.Crossref | GoogleScholarGoogle Scholar |
[7] Tze-ying T, Fu W, Chih-lin C, Mei-fang C, Ching-teh C, Ying-yuan C, Yu-kun L. Clinical and laboratory studies of a new cephalosporin derivative–cefathiamidine. Chin Med J (Engl) 1979; 92 26–36.
| 1:STN:280:DyaE1M7is1yisQ%3D%3D&md5=d25f6d92ed93a4ac9f9b07d4ed4dbfc4CAS |
[8] Wenling C, Xibao Z, Shi F, Minchang W, Ping L, Debiao W, Jinlan Y. Analysis of the antibiotic sensitivity of Neisseria gonorrhoeae in Guangzhou, Peoples Republic of China. Sex Transm Dis 2000; 27 480–2.
| Analysis of the antibiotic sensitivity of Neisseria gonorrhoeae in Guangzhou, Peoples Republic of China.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3MrisF2qtA%3D%3D&md5=9101c9cad87b7e626549570398529c15CAS |
[9] Cao WL, Liang JY, Li XD, Bi C, Yang RD, Liang YH, Li P, Zhong DQ, Ye XD, Zhang XB. Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated from Guangzhou, China, 2000 to 2005 and 2008 to 2013. Sex Transm Dis 2015; 42 27–9.
| Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated from Guangzhou, China, 2000 to 2005 and 2008 to 2013.Crossref | GoogleScholarGoogle Scholar |
[10] World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae (2012). Available online at: http://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/ [verified 20 March 2016].
[11] Liao M, Gu WM, Yang Y, Dillon JA. Analysis of mutations in multiple loci of Neisseria gonorrhoeae isolates reveals effects of PIB, PBP2 and MtrR on reduced susceptibility to ceftriaxone. J Antimicrob Chemother 2011; 66 1016–23.
| Analysis of mutations in multiple loci of Neisseria gonorrhoeae isolates reveals effects of PIB, PBP2 and MtrR on reduced susceptibility to ceftriaxone.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXkvFejsbg%3D&md5=51f9de8acbaa51ab846d247c914f2e74CAS |
[12] Unemo M. Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis 2015; 15 364
| Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge.Crossref | GoogleScholarGoogle Scholar |
[13] Centers for Disease Control and Prevention Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61 590–4.
[14] Bignell C, Unemo M. European STIGEB. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013; 24 85–92.
| European STIGEB. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC2czivV2qsw%3D%3D&md5=80c4ae00fd4bf144a57d5574526189fdCAS |
[15] Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother 2009; 10 555–77.
| The use of cephalosporins for gonorrhea: the impending problem of resistance.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXjtF2mu78%3D&md5=d3a48fd9f5cf688143ffb2a145d85342CAS |
[16] Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007; 44 S84–101.
| Update on the management of gonorrhea in adults in the United States.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2sXksVOrt7Y%3D&md5=ffee9d825f46f6df4544a9c3a137733bCAS |
[17] Akasaka S, Muratani T, Yamada Y, Inatomi H, Takahashi K, Matsumoto T. Emergence of cephem- and aztreonam-high-resistant Neisseria gonorrhoeae that does not produce beta-lactamase. J Infect Chemother 2001; 7 49–50.
| Emergence of cephem- and aztreonam-high-resistant Neisseria gonorrhoeae that does not produce beta-lactamase.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3MzktFOrug%3D%3D&md5=69d6a7a3bb44f5107ff1b009d9cee32bCAS |
[18] Lo JY, Ho KM, Leung AO, Tiu FS, Tsang GK, Lo AC, Tapsall JW. Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection. Antimicrob Agents Chemother 2008; 52 3564–7.
| Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXht1SrtbnP&md5=e6c0005af024e3a62a63cbcbef6f4449CAS |
[19] Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7 1401–22.
| Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhvVSqt7vN&md5=c57a6be1b285376cd21988a4b30a0173CAS |
[20] Chen SC, Yin YP, Dai XQ, Unemo M, Chen XS. Antimicrobial resistance, genetic resistance determinants for ceftriaxone and molecular epidemiology of Neisseria gonorrhoeae isolates in Nanjing, China. J Antimicrob Chemother 2014; 69 2959–65.
| Antimicrobial resistance, genetic resistance determinants for ceftriaxone and molecular epidemiology of Neisseria gonorrhoeae isolates in Nanjing, China.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2MXis1Chsbk%3D&md5=2aec679366e72da69a32c32120347df9CAS |
[21] Thakur SD, Starnino S, Horsman GB, Levett PN, Dillon JR. Unique combined penA/mtrR/porB mutations and NG-MAST strain types associated with ceftriaxone and cefixime MIC increases in a ‘susceptible’ Neisseria gonorrhoeae population. J Antimicrob Chemother 2014; 69 1510–6.
| Unique combined penA/mtrR/porB mutations and NG-MAST strain types associated with ceftriaxone and cefixime MIC increases in a ‘susceptible’ Neisseria gonorrhoeae population.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXotFCqs7s%3D&md5=94537d2acbe1ea16e886757f9a517413CAS |
[22] Powell AJ, Tomberg J, Deacon AM, Nicholas RA, Davies C. Crystal structures of penicillin-binding protein 2 from penicillin-susceptible and -resistant strains of Neisseria gonorrhoeae reveal an unexpectedly subtle mechanism for antibiotic resistance. J Biol Chem 2009; 284 1202–12.
| Crystal structures of penicillin-binding protein 2 from penicillin-susceptible and -resistant strains of Neisseria gonorrhoeae reveal an unexpectedly subtle mechanism for antibiotic resistance.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1MXhsV2juw%3D%3D&md5=1bdca2f9bb7a35edccb65b60ee122f22CAS |
[23] Lee SG, Lee H, Jeong SH, Yong D, Chung GT, Lee YS, Chong Y, Lee K. Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. J Antimicrob Chemother 2010; 65 669–75.
| Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3cXjt1Oisb0%3D&md5=3d2fe6686b116ba7dc1bb08d229848eeCAS |
[24] Lindberg R, Fredlund H, Nicholas R, Unemo M. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother 2007; 51 2117–22.
| Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2sXmtlKrsLk%3D&md5=f71936e49485da261e83ff835ae49c68CAS |
[25] Warner DM, Shafer WM, Jerse AE. Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. Mol Microbiol 2008; 70 462–78.
| Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3cXpslOisw%3D%3D&md5=36338f1cf5e1d747f5449c011c0b842fCAS |
